Literature DB >> 30691274

Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS).

Doaa Shalabi1, Anna Bistline2, Onder Alpdogan3, Saritha Kartan4, Anjali Mishra3, Pierluigi Porcu3, Neda Nikbakht5.   

Abstract

Mycosis fungoides (MF) and Sézary syndrome (SS) are two well-characterized skin limited and leukemic subtypes of cutaneous T-cell lymphoma (CTCL), respectively. Progressive global immune dysfunction and a multitude of specific immunological abnormalities have long been recognized as features of MF and SS. Therefore, a variety of immune-based therapies have been explored and used in the clinic for decades in the attempt to restore the immune imbalance in these malignancies. With recent advances in the development of novel immunotherapies in cancer treatment, new treatment modalities have emerged to complement the existing repertoire. Herein, we provide a comprehensive review of immune evasive mechanisms in MF/SS and summarize the established and emerging immunotherapies for these malignancies. We explain the underlying mechanisms of these immune-based therapies and derive recommendation from results of major clinical trials.

Entities:  

Keywords:  Cutaneous T-cell lymphoma (CTCL); Sézary syndrome (SS); immune evasion; immunotherapy; mycosis fungoides (MF)

Mesh:

Year:  2019        PMID: 30691274     DOI: 10.21037/cco.2019.01.01

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN: 2304-3865


  4 in total

1.  Revisiting Imiquimod for Treatment of Folliculotropic Mycosis Fungoides: A Case Report and Review of the Literature.

Authors:  Doaa Shalabi; Nish Vadalia; Neda Nikbakht
Journal:  Dermatol Ther (Heidelb)       Date:  2019-08-12

2.  Nivolumab in two cases of refractory mycosis fungoides erythroderma.

Authors:  Ewa Chmielowska
Journal:  Cent Eur J Immunol       Date:  2021-12-03       Impact factor: 2.085

3.  Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures.

Authors:  Alberto Herrera; Anthony Cheng; Eleni P Mimitou; Angelina Seffens; Dean George; Michal Bar-Natan; Adriana Heguy; Kelly V Ruggles; Jose U Scher; Kenneth Hymes; Jo-Ann Latkowski; Niels Ødum; Marshall E Kadin; Zhengqing Ouyang; Larisa J Geskin; Peter Smibert; Terkild B Buus; Sergei B Koralov
Journal:  Blood       Date:  2021-10-21       Impact factor: 25.476

Review 4.  The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma.

Authors:  Julia J Scarisbrick; Martine Bagot; Pablo L Ortiz-Romero
Journal:  Br J Haematol       Date:  2020-10-23       Impact factor: 6.998

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.